查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
肌肉萎縮疾病的全球市場：成長、未來前景、競爭分析，2024-2032年
市場調查報告書
商品編碼
1552375

肌肉萎縮疾病的全球市場：成長、未來前景、競爭分析，2024-2032年

Muscle Wasting Disorders Market - Growth, Future Prospects and Competitive Analysis, 2024 - 2032
出版日期: | 出版商: Acute Market Reports | 英文 171 Pages | 商品交期: 最快1-2個工作天內

價格

肌肉消耗性疾病是以肌肉量和力量顯著下降為特徵的疾病，近年來受到越來越多的醫學關注。這些疾病包括多種疾病，從與年齡相關的肌肉減少症到肌肉營養不良等神經肌肉疾病。預計2024年至2032年，肌肉萎縮疾病的市場規模將以 15.5%的年複合成長率成長。

促進因素：人口老化和相關肌肉減少症的增加

肌肉消耗疾病市場的主要驅動力之一是世界人口老化的快速增加。隨著嬰兒潮世代進入老年人口，肌少症（一種與老化密切相關的肌肉無力疾病）的盛行率迅速增加。根據聯合國世界人口老化報告，預計到2050年，60歲及以上的人口數量將增加一倍。這種人口結構的變化導致肌少症病例增加。再加上肌肉無力會倍增殘疾、跌倒、骨折和全因死亡率的風險，醫療保健產業正致力於對抗這種疾病。從荷爾蒙替代療法到力量訓練方案等多種治療策略引起人們的關注，這表明該市場的潛力不斷成長。

機會：神經肌肉疾病基因治療的進展

基因治療領域在解決某些肌肉萎縮疾病的根本原因方面已經顯示出有希望的結果，特別是肌肉萎縮症等遺傳性疾病。最近的案例研究描述了基因療法如何成功引進或修飾特定基因，改善肌肉功能並減緩疾病進展。例如，New England Journal of Medicine上發表的一篇論文詳細介紹了一項基因治療試驗，該試驗顯示患有某些類型肌肉營養不良症的兒童的運動功能得到改善。隨著基因研究的進步和導致這些疾病的突變的發現，開發標靶療法的機會將擴大並有可能改變治療格局。

抑制因素：治療費用高、獲取機會有限

治療和管理方面的進步是有希望的，但成本很高。尖端療法，尤其是基因療法，成本高。其中許多治療不在保險範圍內，給患者帶來了沉重的經濟負擔。此外，由於專門治療中心數量有限，獲得治療的機會有限，主要是在低收入和中等收入國家。Journal of Clinical Medicine上發表的一項研究強調了神經肌肉疾病治療的可用性存在顯著的地區差異，並確定了實現全球採用的市場挑戰。

挑戰：臨床影像的多樣性和診斷難度

肌肉萎縮疾病的臨床症狀差異很大，早期診斷往往很困難。鑑於及時介入對控制病情進展的重要性，這種診斷延遲可能會危及患者的治療結果。肌肉活檢是診斷某些肌肉萎縮疾病的黃金標準之一，但它是侵入性的，並不總是得出結論性的結果。 Muscle & Nerve雜誌上發表的一篇論文描述了一個案例，其中肌肉病理切片檢查產生非特異性結果，需要進一步的診斷程序。這種差異不僅延長了診斷所需的時間，而且還放大了與這些疾病相關的情緒和經濟痛苦。

依類型細分市場

就收入而言，肌肉萎縮症將推動2023年的細分市場。這是由於其普遍存在，尤其是在兒科人群中，以及與其管理相關的高昂成本，包括物理治療、手術干預和藥物治療。對肌肉營養不良症，特別是杜氏肌肉營養不良症（DMD）的研究重點，為基因治療和外顯子跳躍藥物等治療創新鋪平了道路，進一步推動了收入極限。相較之下，肌肉萎縮通常是由神經肌肉疾病和病症（如 ALS、脊髓性肌肉萎縮和神經損傷）引起的，並且具有最高的年複合成長率（CAGR）。意識的提高、早期診斷干預以及針對脊髓性肌肉萎縮症（SMA）等疾病的新興治療管道推動這一成長軌跡，預計這一趨勢將在2024年至2032年持續下去。

最終用戶的市場區隔

2023年，醫院成為肌肉萎縮疾病市場的主要收入來源。這項優點源自於在同一屋簷下提供全面的護理，包括診斷、治療、手術和復健。多學科方法在這些疾病的管理中變得非常重要，有利於醫院的全人照護模式。然而，預計2024年至2032年康復中心的年複合成長率最高。隨著重點轉向改善生活品質、維持運動功能和減緩疾病進展，復健治療在肌肉萎縮疾病管理中的作用變得非常重要。專門從事物理治療、職業治療、語言治療等的中心變得越來越重要。專門從事利基治療領域和家庭護理等其他領域的專科診所也發揮著重要作用，患者尋求個人化和專門的治療，或更喜歡在自己舒適的家中接受治療。

區域市場區隔

北美憑藉其先進的醫療基礎設施、研究計劃和患者意識，在2023年佔據了最大的銷售佔有率。 FDA 批准治療 DMD 和 SMA 等疾病的藥物以及大型製藥公司的存在增強了該地區的主導地位。然而，預計2024年至2032年亞太地區的年複合成長率最高。醫療保健成本上升、對肌肉消耗疾病的認識提高以及診斷基礎設施的改善等因素促成了這一預計的成長。此外，快速成長的人口和未開發市場的存在為該地區的市場擴張提供了有利的機會。

競爭趨勢

肌肉萎縮疾病市場的特徵是競爭激烈，競爭對手包括 Biogen, Inc.、F. Hoffmann-La Roche Ltd、Novartis AG、Ionis Pharmaceuticals, Inc.、Sarepta Therapeutics, Inc.、Nippon Shinyaku Co., Ltd（NS Pharma, Inc.）、PTC Therapeutics, Inc. 和Teva Pharmaceutical Industries Ltd. 在2023年處於領先地位。這些公司主要致力於合併、收購、研究合作關係和積極的研發投資等策略，以維持其市場地位。例如，Roche收購 Spark Therapeutics 鞏固了其在基因治療領域的立足點，特別是針對肌肉萎縮疾病。此外，致力於患者支持計劃以增加獲得藥物的機會，即使成本高昂，也已成為一項值得注意的策略。從2024年到2032年，這些參與者預計將繼續進行技術創新、聯合研究和策略聯盟來推動市場發展。

本報告回答的主要問題

影響肌肉消耗疾病市場成長的關鍵微觀和宏觀環境因素有哪些？

現在和預測期內，就產品領域和地區而言，主要投資領域為何？

2032年之前的預估與市場預測

哪個細分市場在預測期間內年複合成長率最快？

哪個細分市場擁有較大的市場佔有率，為什麼？

低收入和中等收入國家是否投資肌肉萎縮疾病市場？

肌肉消耗疾病市場最大的區域市場是哪一個？

亞太地區、拉丁美洲和中東、非洲等新興市場的市場趨勢和動態是什麼？

推動肌肉消耗疾病市場成長的主要趨勢是什麼？

主要競爭對手是什麼？ 他們提高在全球肌肉消耗疾病市場佔有率的關鍵策略是什麼？

目錄

第1章 前言

  • 報告內容
    • 報告的目的
    • 目標受眾
    • 主要提供
  • 市場區隔
  • 調查方法
    • 第一階段 - 二次調查
    • 第二階段 - 初步調查
    • 第三階段 - 專家評審
    • 先決條件
    • 採用的方法

第2章 執行摘要

第3章 肌肉消耗疾病市場：競爭分析

  • 主要供應商的市場定位
  • 供應商採取的策略
  • 主要產業戰略
  • 層級分析：2023年與2032年

第4章 肌肉​​消耗性疾病市場：宏觀分析與市場動態

  • 簡介
  • 2022-2032年全球肌肉消耗性疾病市場價值
  • 市場動態
    • 市場驅動因素
    • 市場限制因素
    • 主要挑戰
    • 主要機會
  • 促進因素和抑制因素的影響分析
  • See-Saw分析
  • 波特的五力模型
    • 供應商公司的力量
    • 買家的購買力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的對抗關係
  • PESTEL 分析
    • 政治局勢
    • 經濟情勢
    • 技術狀況
    • 法律狀況
    • 社會狀況

第5章 肌肉消耗疾病市場：依類型劃分，2022-2032

  • 市場概覽
  • 成長/利潤分析：2023年與2032年
  • 市場區隔
    • 肌肉營養不良症
    • 肌肉萎縮

第6章 肌肉消耗疾病市場：依治療類型劃分，2022-2032年

  • 市場概覽
  • 成長/利潤分析：2023年與2032年
  • 市場區隔
    • 藥物治療
    • 物理治療
    • 營養治療
    • 手術治療
    • 基因治療
    • 其他

第7章 肌肉消耗性疾病市場：依最終使用者，2022-2032年

  • 市場概覽
  • 成長/利潤分析：2023年與2032年
  • 市場區隔
    • 醫院
    • 復健中心
    • 專科診所
    • 其他

第8章 北美肌肉萎縮疾病市場，2022-2032

  • 市場概覽
  • 肌肉消耗性疾病市場：依類型，2022-2032年
  • 肌肉消耗性疾病市場：依治療類型，2022-2032年
  • 肌肉消耗性疾病市場：依最終使用者，2022-2032年
  • 肌肉消耗性疾病市場：依地區，2022-2032年
    • 北美
      • 美國
      • 加拿大
      • 北美其他地區

第9章 英國/歐盟肌肉萎縮疾病市場，2022-2032年

  • 市場概覽
  • 肌肉消耗性疾病市場：依類型，2022-2032年
  • 肌肉消耗性疾病市場：依治療類型，2022-2032年
  • 肌肉消耗性疾病市場：依最終使用者，2022-2032年
  • 肌肉消耗性疾病市場：依地區，2022-2032年
    • 英國/歐盟
      • 英國
      • 德國
      • 西班牙
      • 義大利
      • 法國
      • 歐洲其他地區

第10章 亞太地區肌肉萎縮疾病市場，2022-2032

  • 市場概覽
  • 肌肉消耗性疾病市場：依類型，2022-2032年
  • 肌肉消耗性疾病市場：依治療類型，2022-2032年
  • 肌肉消耗性疾病市場：依最終使用者，2022-2032年
  • 肌肉消耗性疾病市場：依地區，2022-2032年
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳洲
      • 韓國
      • 亞太地區其他地區

第11章 拉丁美洲肌肉萎縮疾病市場，2022-2032

  • 市場概覽
  • 肌肉消耗性疾病市場：依類型，2022-2032年
  • 肌肉消耗性疾病市場：依治療類型，2022-2032年
  • 肌肉消耗性疾病市場：依最終使用者，2022-2032年
  • 肌肉消耗性疾病市場：依地區，2022-2032年
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲地區

第12章 中東與非洲肌肉萎縮疾病市場，2022-2032

  • 市場概覽
  • 肌肉消耗性疾病市場：依類型，2022-2032年
  • 肌肉消耗性疾病市場：依治療類型，2022-2032年
  • 肌肉消耗性疾病市場：依最終使用者，2022-2032年
  • 肌肉消耗性疾病市場：依地區，2022-2032年
    • 中東、非洲
      • GCC
      • 非洲
      • 其他中東、非洲

第13章 公司簡介

  • Biogen Inc.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Ionis Pharmaceuticals Inc.
  • Sarepta Therapeutics Inc.
  • Nippon Shinyaku Co. Ltd.（NS Pharma Inc.）
  • PTC Therapeutics Inc.
  • Teva Pharmaceutical Industries Ltd.
  • 其他主要公司
Product Code: 374-07-24

Muscle wasting disorders, characterized by the significant reduction of muscle mass and strength, have been the subject of increased medical attention over recent years. These conditions encompass a variety of diseases ranging from sarcopenia, typically related to aging, to neuromuscular disorders like muscular dystrophy. The muscle wasting disorders market is estimated to grow at a CAGR of 15.5% from 2024 to 2032.

Driver: Increasing Aging Population and Associated Sarcopenia

One of the primary drivers for the muscle wasting disorders market is the exponential rise in the global aging population. As the baby boomer generation enters the senior age bracket, the prevalence of sarcopenia - a muscle wasting condition closely associated with aging - has surged. According to the United Nations' report on World Population Aging, the number of individuals aged 60 years or older is expected to double by 2050. This demographic shift has led to an uptick in cases of sarcopenia. Compounded by the fact that muscle wasting exponentially increases the risk of physical disabilities, falls, fractures, and overall mortality, the healthcare industry's focus on combating this disorder has intensified. Treatment strategies ranging from hormone replacement therapies to strength training regimens have garnered attention, signifying the market's expansive potential.

Opportunity: Advancements in Genetic Therapies for Neuromuscular Disorders

The realm of genetic therapies has showcased promising results in addressing the root causes of certain muscle wasting disorders, especially those of a hereditary nature like muscular dystrophy. Recent case studies highlight instances where gene therapies have been successful in introducing or correcting specific genes, leading to improved muscle function and reduced disease progression. For instance, a publication in the New England Journal of Medicine detailed a gene therapy trial that demonstrated improved motor functions in children with a specific type of muscular dystrophy. As genetic research continues to unveil the underlying mutations causing these disorders, the opportunity to develop targeted therapies expands, potentially revolutionizing the treatment landscape.

Restraint: High Treatment Costs and Limited Accessibility

While advancements in treatment and management are promising, they come at a steep price. The costs associated with cutting-edge treatments, especially genetic therapies, are exorbitant. Many of these treatments are not universally covered by insurance, placing a significant financial burden on patients. Furthermore, the limited availability of specialized treatment centers, primarily in low-to-middle-income countries, restricts access to care. A study in the Journal of Clinical Medicine emphasized the significant disparities in the availability of neuromuscular disorder treatments across different regions, elucidating the market's challenges in achieving global reach.

Challenge: Variability in Clinical Presentation and Diagnostic Difficulties

Muscle wasting disorders present with a wide variability in clinical symptoms, often making early diagnosis challenging. Given that timely intervention is crucial to manage progression, this diagnostic delay can lead to compromised patient outcomes. Muscle biopsies, one of the gold standards in diagnosing certain muscle-wasting disorders, are invasive and might not always provide conclusive results. An article in the Muscle & Nerve journal highlighted instances where muscle biopsies yielded non-specific results, necessitating further diagnostic procedures. This variability not only prolongs the diagnostic journey but also amplifies the emotional and financial distress associated with these disorders.

Market Segmentation by Type

In terms of revenue generation, muscular dystrophy led the market segment in 2023. This can be attributed to its prevalence, especially in the pediatric population, and the high costs associated with its management, which include physiotherapy, surgical interventions, and medications. The research focus on dystrophic conditions, especially Duchenne Muscular Dystrophy (DMD), has paved the way for innovations in treatments like gene therapies and exon skipping drugs, further pushing the revenue envelope. In contrast, muscular atrophy, often a consequence of neuromuscular diseases or conditions like ALS, spinal muscular atrophy, or nerve injuries, demonstrated the highest Compound Annual Growth Rate (CAGR). The rising awareness, early diagnostic interventions, and burgeoning therapeutic pipelines for conditions like Spinal Muscular Atrophy (SMA) contribute to this growth trajectory, expected to continue from 2024 to 2032.

Market Segmentation by End-User

In 2023, hospitals emerged as the principal revenue contributor for the muscle wasting disorders market. This dominance was attributed to the comprehensive care offered, including diagnostics, therapeutics, surgeries, and rehabilitation, all under one roof. As multidisciplinary approaches became essential for managing these disorders, hospitals' holistic care model was preferred. However, from 2024 to 2032, it's expected that rehab centers will showcase the highest CAGR. As the emphasis shifts towards improving quality of life, maintaining mobility, and delaying disease progression, the role of rehabilitative therapies in muscle wasting disorders management becomes paramount. These centers, specializing in physiotherapy, occupational therapy, and speech therapy, among others, are becoming increasingly pivotal. Specialty clinics, focusing on niche therapeutic areas, and other segments like home care also play crucial roles, with patients seeking personalized, specialized care or preferring treatments within the comfort of their homes.

Market Segmentation by Region

North America, with its advanced healthcare infrastructure, research initiatives, and patient awareness, held the largest revenue share in 2023. The FDA's approval of drugs for conditions like DMD and SMA, coupled with the presence of major pharmaceutical players, propelled the region's dominance. However, the Asia-Pacific region is anticipated to exhibit the highest CAGR from 2024 to 2032. Factors like increasing healthcare expenditure, rising awareness of muscle wasting disorders, and improving diagnostic infrastructure contribute to this forecasted growth. Moreover, the burgeoning population and the presence of untapped markets present lucrative opportunities for market expansion in this region.

Competitive Trends

The muscle wasting disorders market is characterized by intense competition, with major players like Biogen, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Nippon Shinyaku Co., Ltd. (NS Pharma, Inc.), PTC Therapeutics, Inc., and Teva Pharmaceutical Industries Ltd. leading the charge in 2023. These companies primarily focused on strategies like mergers, acquisitions, research collaborations, and aggressive R&D investments to maintain their market positions. For instance, Roche's acquisition of Spark Therapeutics accentuated its foothold in the gene therapy arena, especially concerning muscle wasting disorders. Additionally, the emphasis on patient assistance programs, ensuring drug accessibility even with high costs, became a notable strategy. Moving forward, from 2024 to 2032, it's expected that these players will continue their innovations, collaborations, and strategic alliances, driving the market forward.

Historical & Forecast Period

This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Muscle Wasting Disorders market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Muscle Wasting Disorders market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Market Segmentation

Type

    • Muscular Dystrophy
  • Duchenne Muscular Dystrophy (DMD)
  • Becker Muscular Dystrophy (BMD)
  • Myotonic Muscular Dystrophy
  • Congenital Muscular Dystrophy
  • Limb-Girdle Muscular Dystrophy
  • Others (Oculopharyngeal Muscular Dystrophy, Emery-Dreifuss Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, etc.)
    • Muscular Atrophy
  • Physiologic Atrophy
  • Pathologic Atrophy
  • Neurogenic Atrophy

Treatment Type

    • Medications
    • Physical Therapy
  • Ultrasound Therapy
  • Electric Simulation
    • Nutritional Therapy
    • Surgery
    • Gene Therapy
    • Others (Occupational Therapy, Respiratory Therapy, Assistive Devices, etc.)

End-User

    • Hospitals
    • Rehab Centers
    • Specialty Clinics
    • Others (Homecare, etc.)

Region Segment (2022-2032; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Muscle Wasting Disorders market?

What are the key investment pockets concerning product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2032.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Muscle Wasting Disorders market?

Which is the largest regional market for Muscle Wasting Disorders market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Muscle Wasting Disorders market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Muscle Wasting Disorders market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Muscle Wasting Disorders Market
  • 2.2. Global Muscle Wasting Disorders Market, By Type, 2023 (US$ Million)
  • 2.3. Global Muscle Wasting Disorders Market, By Treatment Type, 2023 (US$ Million)
  • 2.4. Global Muscle Wasting Disorders Market, By End-User, 2023 (US$ Million)
  • 2.5. Global Muscle Wasting Disorders Market, By Geography, 2023 (US$ Million)
  • 2.6. Attractive Investment Proposition by Geography, 2023

3. Muscle Wasting Disorders Market: Competitive Analysis

  • 3.1. Market Positioning of Key Muscle Wasting Disorders Market Vendors
  • 3.2. Strategies Adopted by Muscle Wasting Disorders Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2023 Versus 2032

4. Muscle Wasting Disorders Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Muscle Wasting Disorders Market Value, 2022 - 2032, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 5.3. Market Segmentation
    • 5.3.1. Muscular Dystrophy
      • 5.3.1.1. Duchenne Muscular Dystrophy (DMD)
      • 5.3.1.2. Becker Muscular Dystrophy (BMD)
      • 5.3.1.3. Myotonic Muscular Dystrophy
      • 5.3.1.4. Congenital Muscular Dystrophy
      • 5.3.1.5. Limb-Girdle Muscular Dystrophy
      • 5.3.1.6. Others (Oculopharyngeal Muscular Dystrophy, Emery-Dreifuss Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, etc.)
    • 5.3.2. Muscular Atrophy
      • 5.3.2.1. Physiologic Atrophy
      • 5.3.2.2. Pathologic Atrophy
      • 5.3.2.3. Neurogenic Atrophy

6. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 6.3. Market Segmentation
    • 6.3.1. Medications
    • 6.3.2. Physical Therapy
      • 6.3.2.1. Ultrasound Therapy
      • 6.3.2.2. Electric Simulation
    • 6.3.3. Nutritional Therapy
    • 6.3.4. Surgery
    • 6.3.5. Gene Therapy
    • 6.3.6. Others (Occupational Therapy, Respiratory Therapy, Assistive Devices, etc.)

7. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 7.3. Market Segmentation
    • 7.3.1. Hospitals
    • 7.3.2. Rehab Centers
    • 7.3.3. Specialty Clinics
    • 7.3.4. Others (Homecare, etc.)

8. North America Muscle Wasting Disorders Market, 2022-2032, USD (Million)

  • 8.1. Market Overview
  • 8.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
  • 8.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
  • 8.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
  • 8.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
    • 8.5.1.North America
      • 8.5.1.1. U.S.
        • 8.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 8.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 8.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 8.5.1.2. Canada
        • 8.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 8.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 8.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 8.5.1.3. Rest of North America
        • 8.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 8.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 8.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

9. UK and European Union Muscle Wasting Disorders Market, 2022-2032, USD (Million)

  • 9.1. Market Overview
  • 9.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
  • 9.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
  • 9.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
  • 9.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
    • 9.5.1.UK and European Union
      • 9.5.1.1. UK
        • 9.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 9.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 9.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 9.5.1.2. Germany
        • 9.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 9.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 9.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 9.5.1.3. Spain
        • 9.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 9.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 9.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 9.5.1.4. Italy
        • 9.5.1.4.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 9.5.1.4.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 9.5.1.4.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 9.5.1.5. France
        • 9.5.1.5.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 9.5.1.5.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 9.5.1.5.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 9.5.1.6. Rest of Europe
        • 9.5.1.6.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 9.5.1.6.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 9.5.1.6.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

10. Asia Pacific Muscle Wasting Disorders Market, 2022-2032, USD (Million)

  • 10.1. Market Overview
  • 10.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
  • 10.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
  • 10.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
  • 10.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
    • 10.5.1.Asia Pacific
      • 10.5.1.1. China
        • 10.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 10.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 10.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 10.5.1.2. Japan
        • 10.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 10.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 10.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 10.5.1.3. India
        • 10.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 10.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 10.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 10.5.1.4. Australia
        • 10.5.1.4.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 10.5.1.4.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 10.5.1.4.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 10.5.1.5. South Korea
        • 10.5.1.5.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 10.5.1.5.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 10.5.1.5.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 10.5.1.6. Rest of Asia Pacific
        • 10.5.1.6.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 10.5.1.6.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 10.5.1.6.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

11. Latin America Muscle Wasting Disorders Market, 2022-2032, USD (Million)

  • 11.1. Market Overview
  • 11.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
  • 11.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
  • 11.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
  • 11.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
    • 11.5.1.Latin America
      • 11.5.1.1. Brazil
        • 11.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 11.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 11.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 11.5.1.2. Mexico
        • 11.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 11.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 11.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 11.5.1.3. Rest of Latin America
        • 11.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 11.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 11.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

12. Middle East and Africa Muscle Wasting Disorders Market, 2022-2032, USD (Million)

  • 12.1. Market Overview
  • 12.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
  • 12.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
  • 12.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
  • 12.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
    • 12.5.1.Middle East and Africa
      • 12.5.1.1. GCC
        • 12.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 12.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 12.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 12.5.1.2. Africa
        • 12.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 12.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 12.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 12.5.1.3. Rest of Middle East and Africa
        • 12.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 12.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 12.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

13. Company Profile

  • 13.1. Biogen, Inc.
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Portfolio
    • 13.1.4. Strategic Initiatives
  • 13.2. F. Hoffmann-La Roche Ltd
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Portfolio
    • 13.2.4. Strategic Initiatives
  • 13.3. Novartis AG
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Portfolio
    • 13.3.4. Strategic Initiatives
  • 13.4. Ionis Pharmaceuticals, Inc.
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Portfolio
    • 13.4.4. Strategic Initiatives
  • 13.5. Sarepta Therapeutics, Inc.
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Portfolio
    • 13.5.4. Strategic Initiatives
  • 13.6. Nippon Shinyaku Co., Ltd. (NS Pharma, Inc.)
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Portfolio
    • 13.6.4. Strategic Initiatives
  • 13.7. PTC Therapeutics, Inc.
    • 13.7.1. Company Overview
    • 13.7.2. Financial Performance
    • 13.7.3. Product Portfolio
    • 13.7.4. Strategic Initiatives
  • 13.8. Teva Pharmaceutical Industries Ltd.
    • 13.8.1. Company Overview
    • 13.8.2. Financial Performance
    • 13.8.3. Product Portfolio
    • 13.8.4. Strategic Initiatives
  • 13.9. Other Notable Players
    • 13.9.1. Company Overview
    • 13.9.2. Financial Performance
    • 13.9.3. Product Portfolio
    • 13.9.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 2 Global Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 3 Global Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 4 Global Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 5 Global Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 6 Global Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 7 North America Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 8 North America Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 9 North America Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 10 North America Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 11 North America Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 12 North America Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 13 U.S. Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 14 U.S. Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 15 U.S. Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 16 U.S. Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 17 U.S. Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 18 U.S. Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 19 Canada Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 20 Canada Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 21 Canada Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 22 Canada Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 23 Canada Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 24 Canada Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 25 Rest of North America Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 26 Rest of North America Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 27 Rest of North America Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 28 Rest of North America Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 29 Rest of North America Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 30 Rest of North America Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 31 UK and European Union Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 32 UK and European Union Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 33 UK and European Union Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 34 UK and European Union Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 35 UK and European Union Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 36 UK and European Union Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 37 UK Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 38 UK Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 39 UK Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 40 UK Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 41 UK Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 42 UK Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 43 Germany Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 44 Germany Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 45 Germany Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 46 Germany Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 47 Germany Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 48 Germany Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 49 Spain Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 50 Spain Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 51 Spain Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 52 Spain Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 53 Spain Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 54 Spain Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 55 Italy Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 56 Italy Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 57 Italy Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 58 Italy Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 59 Italy Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 60 Italy Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 61 France Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 62 France Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 63 France Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 64 France Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 65 France Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 66 France Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 67 Rest of Europe Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 68 Rest of Europe Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 69 Rest of Europe Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 70 Rest of Europe Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 71 Rest of Europe Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 72 Rest of Europe Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 73 Asia Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 74 Asia Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 75 Asia Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 76 Asia Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 77 Asia Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 78 Asia Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 79 China Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 80 China Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 81 China Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 82 China Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 83 China Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 84 China Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 85 Japan Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 86 Japan Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 87 Japan Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 88 Japan Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 89 Japan Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 90 Japan Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 91 India Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 92 India Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 93 India Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 94 India Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 95 India Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 96 India Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 97 Australia Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 98 Australia Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 99 Australia Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 100 Australia Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 101 Australia Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 102 Australia Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 103 South Korea Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 104 South Korea Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 105 South Korea Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 106 South Korea Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 107 South Korea Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 108 South Korea Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 109 Latin America Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 110 Latin America Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 111 Latin America Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 112 Latin America Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 113 Latin America Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 114 Latin America Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 115 Brazil Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 116 Brazil Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 117 Brazil Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 118 Brazil Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 119 Brazil Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 120 Brazil Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 121 Mexico Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 122 Mexico Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 123 Mexico Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 124 Mexico Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 125 Mexico Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 126 Mexico Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 127 Rest of Latin America Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 128 Rest of Latin America Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 129 Rest of Latin America Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 130 Rest of Latin America Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 131 Rest of Latin America Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 132 Rest of Latin America Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 133 Middle East and Africa Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 134 Middle East and Africa Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 135 Middle East and Africa Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 136 Middle East and Africa Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 137 Middle East and Africa Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 138 Middle East and Africa Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 139 GCC Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 140 GCC Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 141 GCC Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 142 GCC Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 143 GCC Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 144 GCC Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 145 Africa Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 146 Africa Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 147 Africa Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 148 Africa Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 149 Africa Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 150 Africa Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 151 Rest of Middle East and Africa Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 152 Rest of Middle East and Africa Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 153 Rest of Middle East and Africa Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 154 Rest of Middle East and Africa Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 155 Rest of Middle East and Africa Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 156 Rest of Middle East and Africa Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

List of Figures

  • FIG. 1 Global Muscle Wasting Disorders Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Muscle Wasting Disorders Market: Quality Assurance
  • FIG. 5 Global Muscle Wasting Disorders Market, By Type, 2023
  • FIG. 6 Global Muscle Wasting Disorders Market, By Treatment Type, 2023
  • FIG. 7 Global Muscle Wasting Disorders Market, By End-User, 2023
  • FIG. 8 Global Muscle Wasting Disorders Market, By Geography, 2023
  • FIG. 9 Market Geographical Opportunity Matrix - Global Muscle Wasting Disorders Market, 2023

FIG. 10Market Positioning of Key Muscle Wasting Disorders Market Players, 2023

FIG. 11Global Muscle Wasting Disorders Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032

  • FIG. 12 Global Muscle Wasting Disorders Market, By Type, 2023 Vs 2032, %
  • FIG. 13 Global Muscle Wasting Disorders Market, By Treatment Type, 2023 Vs 2032, %
  • FIG. 14 Global Muscle Wasting Disorders Market, By End-User, 2023 Vs 2032, %
  • FIG. 15 U.S. Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 16 Canada Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 17 Rest of North America Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 18 UK Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 19 Germany Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 20 Spain Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 21 Italy Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 22 France Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 23 Rest of Europe Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 24 China Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 25 Japan Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 26 India Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 27 Australia Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 28 South Korea Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 29 Rest of Asia Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 30 Brazil Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 31 Mexico Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 32 Rest of Latin America Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 33 GCC Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 34 Africa Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 35 Rest of Middle East and Africa Muscle Wasting Disorders Market (US$ Million), 2022 - 2032